Lisata sues Kuva Labs, cuts 72% of staff after merger collapse

Lisata Therapeutics has terminated its merger agreement with Kuva Labs and sued the company in the Delaware Court of Chancery. The clinical-stage pharmaceutical company is seeking damages for stockholders and a $2,000,000 termination fee owed under the deal.

The two companies signed an Agreement and Plan of Merger on March 6, 2026, involving Kuva Labs and its subsidiary Kuva Acquisition Corp. Lisata says Kuva breached that agreement, prompting the termination and legal action.

To preserve cash, Lisata has cut roughly 72% of its full-time employees, including its executive vice president of R&D and chief medical officer. Some departing staff may be retained as external consultants.

Lisata's board is evaluating strategic alternatives to boost stockholder value. Options include an acquisition, merger, reverse merger, asset sales, or liquidation and dissolution.

Lisata has set no timetable for its strategic review and will not comment further until its board approves a definitive course of action. With most of its workforce gone, the company's path forward hinges on that outcome.

The collapse underscores how fragile small-cap biotech deals can be, leaving clinical-stage firms to weigh drastic cost cuts against the search for a new lifeline.